ABSTRACT
PURPOSE: This trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group compares the use of high-dose therapy (HDT) as part of primary treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide followed by involved-field (IF) radiotherapy in a randomized, multicenter, phase III study. PATIENTS AND METHODS: Three hundred twelve patients with "aggressive" non-Hodgkin's lymphoma aged Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
, L-Lactate Dehydrogenase/blood
, Lymphoma, Non-Hodgkin/enzymology
, Lymphoma, Non-Hodgkin/therapy
, Stem Cell Transplantation
, Antineoplastic Combined Chemotherapy Protocols/administration & dosage
, Carmustine/administration & dosage
, Chemotherapy, Adjuvant
, Cyclophosphamide/administration & dosage
, Cytarabine/administration & dosage
, Doxorubicin/administration & dosage
, Drug Administration Schedule
, Etoposide/administration & dosage
, Female
, Germany
, Humans
, Lymphoma, Non-Hodgkin/drug therapy
, Lymphoma, Non-Hodgkin/radiotherapy
, Male
, Melphalan/administration & dosage
, Middle Aged
, Prednisolone/administration & dosage
, Prognosis
, Prospective Studies
, Radiotherapy, Adjuvant
, Risk
, Survival Analysis
, Transplantation, Autologous
, Treatment Outcome
, Vincristine/administration & dosage
